Cargando…
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
BACKGROUND: Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC. METHODS: Patients with PROC wer...
Autores principales: | Lindemann, Kristina, Gibbs, Emma, Åvall-Lundqvist, Elisabeth, dePont Christensen, Rene, Woie, Kathrine, Kalling, Marten, Auranen, Annika, Grenman, Seija, Hoegberg, Thomas, Rosenberg, Per, Skeie-Jensen, Tone, Hjerpe, Elisabet, Dørum, Anne, Gebski, Val, Kristensen, Gunnar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5318972/ https://www.ncbi.nlm.nih.gov/pubmed/28118323 http://dx.doi.org/10.1038/bjc.2016.435 |
Ejemplares similares
-
Protein markers of cancer-associated fibroblasts and tumor-initiating cells reveal subpopulations in freshly isolated ovarian cancer ascites
por: Wintzell, My, et al.
Publicado: (2012) -
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer
por: Hjerpe, Elisabet, et al.
Publicado: (2013) -
Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study
por: Laasik, Maren, et al.
Publicado: (2019) -
Survival in endometrial cancer in relation to minimally invasive surgery or open surgery – a Swedish Gynecologic Cancer Group (SweGCG) study
por: Borgfeldt, Christer, et al.
Publicado: (2021) -
Innovation policies
por: KALLING, Thomas
Publicado: (2014)